Fujifilm Holdings Corp TSE:4901

FUJIFILM : (Correction) Notice Regarding Partial Corrections to the Financial Results (Consolidated) for the Fiscal Year Ended March 31, 2026

Published

Source: MarketScreener



FUJIFILM Holdings Corporation

Teiichi Goto

President and Chief Executive Officer

May 12, 2026

(Correction) Notice Regarding Partial Corrections to the Financial Results (Consolidated) for the Fiscal Year Ended March 31, 2026

FUJIFILM Holdings Corporation (the "Company") hereby announces that certain numerical data in the Financial Results (Consolidated) for the Fiscal Year Ended March 31, 2026 disclosed on May 12, 2026 at 14:00 (JST) have been corrected.

  1. Reasons for the corrections

    Errors were identified in the outlook for the fiscal year ending March 31, 2027 in page 5 of the Outlook for the Fiscal Year ending March 31, 2027 of the section (1) Analysis of Results of Operations in 1. ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION.

  2. Details of corrections Corrections are underlined below

Page 5: Outlook for the Fiscal Year ending March 31, 2027 (Before Correction)

The impact of fluctuations in energy costs and raw material prices arising from heightened tensions in the Middle East has not been factored into the full-year outlook, as significant uncertainty remains regarding the situation going forward. In addition, sales in the Middle East have been only marginally affected, and the impact on revenue has likewise not been factored into the full-year outlook. However, as a risk scenario, if crude oil prices were to remain at USD 100 per barrel, we estimate a negative impact on operating profit of approximately ¥30.0 billion to ¥40.0 billion per quarter.

(After Correction)

The impact of fluctuations in energy costs and raw material prices arising from heightened tensions in the Middle East has not been factored into the full-year outlook, as significant uncertainty remains regarding the situation going forward. In addition, sales in the Middle East have been only marginally affected, and the impact on revenue has likewise not been factored into the full-year outlook. However, as a risk scenario, if crude oil prices were to remain at USD 100 per barrel, we estimate a negative impact on operating profit of approximately ¥3.0 billion to ¥4.0 billion per quarter.

1





Financial Results (Consolidated) for the Fiscal Year Ended March 31, 2026 FUJIFILM Holdings Corporation May 12, 2026

Teiichi Goto URL: https://holdings.fujifilm.com/en

President and Chief Executive Officer

Date of annual shareholders' meeting: June 26, 2026 Projected date of the beginning of cash dividends: June 29, 2026 Projected date of annual securities report: June 24, 2026

Reference materials regarding operating results of the current fiscal year to be prepared: Yes Meeting to explain operating results of the current fiscal year to be held: Yes

(Consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.)

  1. Results of the Fiscal Year Ended March 31, 2026 (From April 1, 2025 to March 31, 2026)

    1. OPERATING RESULTS Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

      %: Changes from the corresponding period of the previous fiscal year

      Revenue

      Operating income

      Income before income taxes

      Net income attributable to FUJIFILM Holdings

      %

      %

      %

      %

      Year ended March 31, 2026

      3,356,969

      5.0

      350,210

      6.1

      366,629

      7.6

      276,735

      6.0

      Year ended March 31, 2025

      3,195,828

      7.9

      330,155

      19.3

      340,594

      7.3

      260,951

      7.2

      Note: Comprehensive income

      Year ended March 31, 2026 ¥580,678 million (+131.4 %) Year ended March 31, 2025 ¥250,924 million (-51.7%)

      Net income attributable

      to FUJIFILM Holdings per share

      Net income attributable to FUJIFILM Holdings per share

      (Assuming full dilution)

      Return on FUJIFILM Holdings shareholders' equity

      Ratio of income before income taxes to total assets

      Ratio of operating income to revenue

      Yen

      Yen

      %

      %

      %

      Year ended March 31, 2026

      229.65

      229.45

      7.7

      6.5

      10.4

      Year ended March 31, 2025

      216.67

      216.46

      8.0

      6.8

      10.3

      (Ref) Equity in net earnings of affiliated companies

      Year ended March 31, 2026 ¥1,929 million Year ended March 31, 2025 ¥(1,320) million

    2. FINANCIAL POSITION Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

      Total assets

      Total equity (Net asset)

      FUJIFILM Holdings shareholders' equity

      FUJIFILM Holdings shareholders' equity ratio to total assets

      FUJIFILM Holdings shareholders' equity per share

      %

      Yen

      Year ended March 31, 2026

      6,053,776

      3,844,385

      3,839,550

      63.4

      3,185.79

      Year ended March 31, 2025

      5,249,908

      3,352,682

      3,348,480

      63.8

      2,779.50

    3. CASH FLOWS Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

    Net cash provided by operating activities

    Net cash used in investing activities

    Net cash used in financing activities

    Cash and cash equivalents

    at the end of year

    Year ended March 31, 2026

    410,555

    (554,604)

    120,249

    170,553

    Year ended March 31, 2025

    428,162

    (541,953)

    108,883

    172,111

  2. Cash Dividends Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

    Cash dividends per share

    Total cash dividends

    Consolidated pay out ratio

    Ratio of cash dividends to shareholders' equity

    1st Quarter

    2nd Quarter

    3rd Quarter

    Year End

    Year Total

    Year ended March 31, 2025

    Year ended March 31, 2026

    Yen

    -

    -

    Yen

    30.00

    35.00

    Yen

    -

    -

    Yen

    35.00

    35.00

    Yen

    65.00

    70.00

    78,358

    84,419

    %

    30.0

    30.5

    %

    2.4

    2.3

    Year ending March 31, 2027

    (Forecast)

    -

    37.50

    -

    37.50

    75.00

    32.0

  3. Forecast for the Fiscal Year Ending March 31, 2027 (From April 1, 2026 to March 31, 2027)

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

%: Changes from the corresponding period of the previous fiscal year

Revenue

Operating income

Income before income taxes

Net income attributable to FUJIFILM Holdings

Net income attributable to FUJIFILM Holdings per share

For the Year ending March 31, 2027

%

%

%

%

Yen

3,470,000

3.4

365,000

4.2

375,000

2.3

280,000

1.2

234.19

Note: The Company resolved at the meeting of the Board of Directors held on March 30, 2026 to carry out a share repurchase, and the share repurchase pursuant to this resolution was completed on April 30, 2026. (For details, please refer to the notice dated May 7, 2026, titled "Notice Regarding Completion of Share Repurchase and Cancellation of Treasury Stock.")

The weighted average number of shares outstanding, which is used as the basis for the calculation of net income attributable to FUJIFILM Holdings per share in the consolidated earnings forecast for the fiscal year ending March 31, 2027, is calculated by deducting the number of treasury stock repurchased as described above from the number of issued shares outstanding (excluding treasury stock) as of March 31, 2026.

Notes

  1. Changes in status of material subsidiaries during the period (Company newly consolidated or removed from consolidation): None

  2. Changes in accounting principles

    1. Changes in accounting policies accompanying amendment of accounting standards: None

    2. Other changes in accounting policies: None

  3. Number of shares outstanding

    As of March 31, 2026

    1,243,877,184

    As of March 31, 2025

    1,243,877,184

    As of March 31, 2026

    38,547,368

    As of March 31, 2025

    39,043,399

    Year ended March 31, 2026

    1,203,646,419

    Year ended March 31, 2025

    1,203,306,280

    1. Issued (including treasury stock):

    2. Treasury stock:

    3. Average number of shares:

This report is not reviewed.

Explanation of Appropriate Use of Forecast and Other Special Items

Statements regarding future events including forecasts of operating results are based on limited available information and reasonable assumptions as of today. The Company does not have the intention of guaranteeing the realization of future performance. Actual operating results are always subject to change significantly due to various matters. Assumptions for the forecast and warnings for users of the forecast are mentioned in the page 5, Outlook for the Fiscal Year ending March 31, 2027 of the section (1) Analysis of Results of Operations in 1. ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION.

[INDEX]

  1. ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION

    1. Analysis of Consolidated Operating Results… P.2

    2. Analysis of Consolidated Financial Position …………………………………………….……… P.5

    3. Basic Policy Regarding Distribution of Profits and Dividends Applicable to the Fiscal Year under Review and Subsequent Fiscal Year ……………………………………………………...

      P.6

  2. CORPORATE STRUCTURE OF THE FUJIFILM GROUP P.6

  3. CORPORATE DIRECTION ……………………………………………………………………………. P.7

  4. BASIC RATIONALE FOR SELECTION OF ACCOUNTING STANDARDS ………………………. P.10

  5. CONSOLIDATED FINANCIAL STATEMENTS

    1. Consolidated Balance Sheets ……………………………………………………………………. P.11

    2. Consolidated Statements of Income and Consolidated Statements of Comprehensive Income ... P.14 (Consolidated Statements of Income) …………………………………………………...………. P.14 Year ended March 31 …………………………………………………...……………………….. P.14 Three months ended March 31 …………………………………………………...……………… P.15 (Consolidated Statements of Comprehensive Income) …………………………………..…….... P.16 Year ended March 31 …………………………………………………...……………………….. P.16 Three months ended March 31 …………………………………………………………………... P.16

    3. Consolidated Statements of Changes in Shareholders' Equity ………………………………….. P.17

    4. Consolidated Statements of Cash Flows ………………………………………………………… P.18

    5. Notes to Consolidated Financial Statements ……………………………………………………. P.19 (Notes Relating to the Going Concern Assumption) ……………………………………………. P.19 (Summary of Significant Accounting Policies) ………………………………………………….. P.19 (Segment Information) …………………………………………………………………………... P.20

      1. Year ended March 31 ……………………………………………………………………… P.20

      2. Three months ended March 31 …………………………………………………..………… P.23 (Amounts Per Share of Common Stock) ……………………………………………………….... P.24 (Significant Subsequent Events) ………………………………………………………………… P.24

  1. ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION

    1. Analysis of Consolidated Operating Results

      Amount Unit: Billions of yen

      Year ended March 31, 2026 (From April 1,

      2025 to March 31,

      2026)

      Year ended March 31, 2025 (From April 1,

      2024 to March 31,

      2025)

      Change (Amount)

      Change (%)

      Domestic revenue

      Overseas revenue

      34.8%

      65.2%

      1,168.7

      2,188.3

      34.4%

      65.6%

      1,099.3

      2,096.5

      69.4

      91.8

      6.3%

      4.4%

      Revenue

      100.0%

      3,357.0

      100.0%

      3,195.8

      161.1

      5.0%

      Operating income

      10.4%

      350.2

      10.3%

      330.2

      20.1

      6.1%

      Income before income taxes

      10.9%

      366.6

      10.7%

      340.6

      26.0

      7.6%

      Net income attributable to FUJIFILM Holdings

      8.2%

      276.7

      8.2%

      261.0

      15.8

      6.0%

      Exchange rates (Yen / US$)

      Exchange rates (Yen / Euro)

      ¥151

      ¥175

      ¥152

      ¥164

      (¥1)

      ¥11

      In the fiscal year ended March 31, 2026, the Fujifilm Group recorded ¥3,357.0 billion in consolidated revenue (up 5.0% year-over-year), reflecting sales increases mainly in the bio CDMO, semiconductor materials and Imaging businesses. Operating income increased to ¥350.2 billion (up 6.1% year-over-year). Consolidated income before income taxes amounted to ¥366.6 billion (up 7.6% year-over-year) and consolidated net income attributable to FUJIFILM Holdings amounted to ¥276.7 billion (up 6.0% year-over-year). The effective currency exchange rates for the U.S. dollar and the euro against the yen were ¥151 and ¥175, respectively,

      Revenue by Operating Segment Amount Unit: Billions of yen

      Segment

      Year ended March 31, 2026 (From April 1,

      2025 to March 31,

      2026)

      Year ended March 31, 2025 (From April 1,

      2024 to March 31,

      2025)

      Change (Amount)

      Change (%)

      Healthcare

      1,098.9

      1,047.8

      51.2

      4.9%

      Electronics

      456.2

      407.6

      48.6

      11.9%

      Business Innovation

      1,174.8

      1,198.5

      (23.7)

      (2.0%)

      Imaging

      627.1

      542.0

      85.1

      15.7%

      Consolidated Total

      3,357.0

      3,195.8

      161.1

      5.0%

      Operating Income by Operating Segment Amount Unit: Billions of yen

      Segment

      Year ended March 31, 2026 (From April 1,

      2025 to March 31,

      2026)

      Year ended March 31, 2025 (From April 1,

      2024 to March 31,

      2025)

      Change (Amount)

      Change (%)

      Healthcare

      63.6

      79.9

      (16.2)

      (20.3%)

      Electronics

      100.9

      75.1

      25.8

      34.4%

      Business Innovation

      63.7

      74.6

      (10.9)

      (14.6%)

      Imaging

      160.0

      139.2

      20.8

      14.9%

      Corporate expenses etc.

      (38.0)

      (38.6)

      0.6

      -

      Consolidated Total

      350.2

      330.2

      20.1

      6.1%

      * From the consolidated first three months of the fiscal year, the chemical reagents business was reclassified from the Electronics segment, where it was included in the AF (Advanced Functional) materials business, to the Healthcare segment. Figures for the year ago quarter are also based on the segment classification after the above change.

      Healthcare Segment

      In the Healthcare segment, consolidated revenue amounted to ¥1,098.9 billion (up 4.9% year-over-year). Consolidated operating income amounted to ¥63.6 billion (down 20.3% year-over-year).

      In the medical systems business, sales of endoscopes continued to increase in key markets, including Japan, the

      U.S. and Europe. Medical IT sales also grew as system services sales were solid in Japan, the U.S., Europe, the Middle East and other markets, mainly for the SYNAPSE Picture Archiving and Communication System (PACS). In addition, sales of in-vitro diagnostics (IVD) increased, including strong sales for FUJI DRI-CHEM blood biochemical testing equipment and materials. However, overall revenue for the medical systems business remained at the previous fiscal year's level due to factors such as lower demand for medical supplies in China. In March 2026, we launched CALNEO Xair PLUS, a lightweight and compact, mobile x-ray imaging device that helps streamline examination workflows, and added new products in the bronchoscope lineup, EB-840S and EB-840T, equipped with HD image CMOS sensors. We will continue to leverage our proprietary technologies to provide a wide range of products and services that meet the various demands of medical settings, to contribute to further streamlining diagnoses, advancing the quality of healthcare, and maintaining and promoting people's health.

      In the bio CDMO business, revenue increased, driven mainly by contributions from the start of new large-scale manufacturing facilities in Denmark in the previous fiscal year, along with the resumption of operations of small- to medium-scale manufacturing facilities at the Texas site, which implemented operational adjustments during the previous fiscal year. In the fiscal year under review, we launched a new large-scale manufacturing plant in North Carolina, the United States, and commenced operations of eight 20,000-liter mammalian cell culture bioreactors, representing the first phase investment at the facility. Furthermore, in February 2026, we opened a drug substance manufacturing building for antibody drugs and a process development laboratory at our UK site. By responding to rapidly growing demand for antibody drugs contract manufacturing, we will further accelerate our business growth.

      The LS (Life Sciences) solutions business*¹ posted higher revenue due to life sciences business delivering higher sales of culture media driven by increased usage by major pharmaceutical companies, as well as strong reagent sales amid a recovery in market demand, while the pharmaceutical business saw growth in revenue mainly with an expansion in contract manufacturing of investigational drugs for domestic COVID-19 vaccines.

      *¹ The LS solutions business comprises life sciences business, pharmaceutical business, consumer healthcare business and CRO (Contract Research Organization) business.

      Electronics Segment

      In the Electronics segment, consolidated revenue amounted to ¥456.2 billion (up 11.9% year-over-year). Consolidated operating income amounted to ¥100.9 billion (up 34.4% year-over-year).

      The semiconductor market, having experienced a period of stable growth due to the use of semiconductors in a wide range of products such as automobiles and home appliances, is now undergoing significant growth due to rising demand for AI semiconductors. Our semiconductor materials business has steadily captured this demand for AI semiconductors, resulting in a boost in revenue. Sales to major foundries continued to perform well, and sales to major semiconductor manufacturers in the U.S. and South Korea are also recovering. By product category, sales of NTI developers, copper interconnect CMP slurries-both of which we hold the top global market share-and advanced photoresists have grown in line with miniaturization and the increasing number of interconnect layers.

      With respect to back-end materials, sales of liquid polyimide for interlayer insulation films used in inter-chip connections have also grown, driven by expanding demand for advanced packaging for AI semiconductors. In February 2026, we completed a ¥5.0 billion investment in Rapidus Corporation, a company which aims to mass-produce leading-edge logic semiconductors. Through this investment, we are committed to realizing domestic mass production of leading-edge semiconductors and the development of Japan's semiconductor industry. Moreover, by providing Rapidus with a wide range of semiconductor materials and technologies, we will strongly support the company's development and manufacturing of leading-edge semiconductors. Additionally, by working closely with Rapidus on next-generation process development, we will enhance our technological capabilities and accelerate the development of materials for next-generation semiconductors.

      In the AF (Advanced Functional) materials business, revenue increased due to the growing adoption of new display materials and strong sales of semiconductor resist materials.

      Business Innovation Segment

      In the Business Innovation segment, consolidated revenue amounted to ¥1,174.8 billion (down 2.0% year-over-year).

      Consolidated operating income amounted to ¥63.7 billion (down 14.6% year-over-year).

      In the business solutions business, revenue increased primarily due to growth in sales of digital transformation (DX)-related solutions driven by replacement demand in Japan with the end of Windows 10 support, as well as growth in services provided to local governments. In March 2026, we acquired ETG Global Information Technology Services Inc. in Turkey. By combining ETG Global's technical capabilities and IT talent base with the business foundation we have cultivated to date, we will globally expand our ERP system sales and implementation support business.

      The office solutions business posted lower revenue, mainly due to the sluggish market conditions in China and Oceania, as well as a drop in sales in the Asia-Pacific region primarily caused by the discontinuation of low-profit products, as well as a decline in exports to Europe and the U.S.

      The graphic communications business posted lower revenue due to lower sales of printing-plate materials in Europe and the U.S. and the discontinuation of unprofitable plate-making materials in the analog printing field. We launched Revoria Press PC2120 in December 2025, a production printer that automates and streamlines printing operations using proprietary AI technology. Then in March 2026, we began offering Revoria Cloud Production, a cloud service that leverages AI for a more efficient print production management operations.

      Imaging Segment

      In the Imaging segment, consolidated revenue amounted to ¥627.1 billion (up 15.7% year-over-year). Consolidated operating income amounted to ¥160.0 billion (up 14.9% year-over-year).

      The consumer imaging business posted higher revenue, as sales of the instax instant photo systems continued to expand, surpassing cumulative sales of 100 million units. A wide variety of models popular among a broad range of users continue to have a solid growth in sales, including the mainstay models instax mini 12 and instax mini Evo, along with models launched in the previous fiscal year, such as instax WIDE 400, instax Link 3 and instax WIDE Evo. We also launched the entry-level instax mini 41 with a classic design in April 2025, and instax mini LiPlay+ in November 2025, which comes with an advanced version of a feature that combines sound and still images.

      Moreover, in January 2026, we launched instax mini Evo Cinema, an instant camera that can capture both videos (which users can "hand over" to others) and still images, and is equipped with the Eras Dial that recreates the appearance of footage from the 1930s to the current decade. We also launched instax mini Link+, a premium model in the mini Link smartphone printer series, offering novel ways to enjoy instax photos. Additionally, in December 2025, we announced our plan to expand the production facilities of instax films to meet growing global demand.

      We will continue to expand the world of instax, enabling people to enjoy instant photo printing and further enhancing the value and joy of photography.

      In the professional imaging business, expanded sales of digital cameras contributed to higher revenue. In addition to solid sales of models launched in the previous fiscal year, the growth was driven by new products launched in the fiscal year under review, such as FUJIFILM GFX100RF, FUJIFILM X-HF1 ("X half"), FUJIFILM X-E5 and FUJIFILM X-T30 III. Further, we launched FUJIFILM GFX ETERNA 55 in the fiscal year under review, our first dedicated filmmaking camera, and we will continue to provide new value to filmmaking sites through our color reproduction, large format rendering, and optical performance capabilities. We will continue to provide attractive products for digital camera users and the video industry by expanding our range of offerings, from the outstanding image quality with large format sensors in the GFX series and the best balance of image quality and size in the X series, to such new concept cameras as FUJIFILM GFX100RF, X half and FUJIFILM GFX ETERNA 55.

      Outlook for the Fiscal Year ending March 31, 2027

      Amount Unit: Billions of yen

      Outlook for the Fiscal Year ending March 31, 2027

      Actual results for the Fiscal Year ended March 31, 2026

      Change (% / Amount)

      Revenue

      3,470.0

      3,357.0

      3.4%

      Operating income

      365.0

      350.2

      4.2%

      Income before income taxes

      375.0

      366.6

      2.3%

      Net income attributable to FUJIFILM

      Holdings

      280.0

      276.7

      1.2%

      ROE (%)

      7.8

      7.7

      0.1pt

      ROIC (%)

      5.6

      5.5

      0.1pt

      Exchange rates (Yen / US$)

      Exchange rates (Yen / Euro)

      ¥150

      ¥175

      ¥151

      ¥175

      ¥(1)

      ¥-

      For the fiscal year ending March 31, 2027, the Company projects ¥3,470.0 billion in consolidated revenue (up 3.4% year-over-year), ¥365.0 billion in operating income (up 4.2% year-over-year), ¥375.0 billion in income before income taxes (up 2.3% year-over-year) and ¥280.0 billion in net income attributable to FUJIFILM Holdings (up 1.2% year-over-year).

      The projected currency exchange rates for the U.S. dollar and the euro against the yen for the fiscal year ending March 31, 2027 are ¥150 and ¥175, respectively.

      The impact of fluctuations in energy costs and raw material prices arising from heightened tensions in the Middle East has not been factored into the full-year outlook, as significant uncertainty remains regarding the situation going forward. In addition, sales in the Middle East have been only marginally affected, and the impact on revenue has likewise not been factored into the full-year outlook. However, as a risk scenario, if crude oil prices were to remain at USD 100 per barrel, we estimate a negative impact on operating profit of approximately ¥3.0 billion to ¥4.0 billion per quarter.

    2. Analysis of Consolidated Financial Position

      (Assets, Liabilities, Shareholders' Equity and Cash Flows)

      At the end of the fiscal year ended March 31, 2026, total assets increased by ¥803.9 billion to ¥6,053.8 billion compared with the end of the previous fiscal year (March 31, 2025) mainly due to an increase in property, plant and equipment. Total liabilities increased by ¥312.2 billion to ¥2,209.4 billion. Shareholders' equity increased by

      ¥491.1 billion to ¥3,839.6 billion. As a result, the current ratio decreased by 3.9 percentage points to 136.6%, the debt-equity ratio increased by 0.8 percentage points to 57.5%, and the equity ratio decreased by 0.4 percentage points to 63.4% compared with the end of the previous fiscal year. The Company maintains a stable level of asset liquidity and a sound capital structure.

      In the fiscal year ended March 31, 2026, net cash provided by operating activities totaled ¥410.6 billion. Net cash used in investing activities amounted to ¥554.6 billion due to the acquisition of property, plants, equipment and other factors. As a result, free cash flow, or the sum of cash flow from operating and investing activities, was negative ¥144.0 billion. Net cash provided by financing activities amounted to ¥120.2 billion, mainly due to proceeds from long-term debts. As a result, cash and cash equivalents at the end of the fiscal year ended March 31, 2026 amounted to ¥170.6 billion, down ¥1.6 billion from the end of the previous fiscal year (March 31, 2025), as a result of the above cash flows and foreign exchange fluctuations.

      (Reference) Cash Flow Related Indices (Consolidated)

      Year ended March 31, 2026

      (From April 1, 2025 to

      March 31, 2026)

      Year ended March 31, 2025

      (From April 1, 2024 to

      March 31, 2025)

      Ratio of shareholders' equity to total assets

      (%)

      63.4

      63.8

      Ratio of market capitalization to total assets

      (%)

      59.1

      65.3

      Ratio of interest-bearing debt to operating

      cash flow (years)

      2.2

      1.6

      Interest coverage ratio (times)

      82.2

      48.9

      Ratio of shareholders' equity to total assets : Shareholders' equity / Total assets

      Ratio of market capitalization to total assets : Market capitalization (Year-end closing price x No. of shares outstanding at year-end*) / Total assets

      *Excluding treasury shares

      Ratio of interest-bearing debt to operating cash : Interest-bearing debts (corporate bond securities and short- and long-term debts) flow / Operating cash flow

      Interest coverage ratio : Operating cash flow / interest paid

    3. Basic Policy Regarding Distribution of Profits and Dividends Applicable to the Fiscal Year under Review and Subsequent Fiscal Year

    In addition to reflecting consolidated performance trends, dividends will be determined by taking into account such factors as the level of funds required to increase our corporate value in the future, including M&As, capital expenditures and R&D investments aimed at further expanding growth businesses. We have the policy on shareholder returns that puts emphasis on cash dividends, targeting the dividend payout ratio of 30%. Furthermore, we have flexibly conducted share repurchases in response to stock price trends while taking our cash flow at the time into account. As part of this policy, we have announced the execution of a share repurchase program with an upper limit of ¥30.0 billion in March 2026.

    We are planning the year-end dividend to be ¥35.0 per share, and together with the interim dividend of ¥35.0 per share, the total cash dividend for the fiscal year under review is expected to amount to ¥70.0 per share.

    In the fiscal year ending March 31, 2027, we plan to pay an interim dividend of ¥37.5 per share and a year-end dividend of ¥37.5 per share, for a total of ¥75.0 per share for the year.

  2. CORPORATE STRUCTURE OF THE FUJIFILM GROUP

    The disclosure is omitted since there are no significant changes in the business and group organizational structure from the latest Annual Securities Report filed on June 25, 2025.

  3. CORPORATE DIRECTION

    On the occasion of our 90th anniversary, we established the Fujifilm Group's Purpose "Giving our world more smiles." Since our foundation, we have brought smiles to people's faces through our products and services based on our advanced and unique technologies. As we move towards our 100th anniversary and beyond, we remain committed to resolving social issues through all of our businesses, and each and every one of our employees will continue to challenge themselves with their aspirations to bring happy smiles to people around the world many times over. To achieve the Group Purpose, it is essential to: (1) develop new products and solutions, and invest in facilities to drive our sustainable business growth, (2) address Environmental, Social and Governance (ESG) issues to advance our efforts towards environmental sustainability, protection of human rights and ethical supply chain management, (3) invest in our people, implement innovations in developing our talent, enhance working conditions, and increase compensation standards as we focus on employee engagement and the full utilization of every employee's unique skills and capabilities, and (4) ensure shareholder returns and deliver value to a broad range of stakeholders. To generate profits to fund these activities, the Group will increase its earning power by focusing on strong businesses that ensure long-term competitive advantage, and evolve into an even more profitable company by pursuing both economic and social value. Furthermore, by reinvesting the profits earned in (1), (2), (3) and (4) above, we will create a sustainable positive cycle.

    In August 2017, we established our long-term CSR plan Sustainable Value Plan 2030 (hereinafter "SVP2030"). VISION2030, our medium-term management plan established in April 2024, is a concrete action plan to realize the goals of SVP2030. In VISION2030, we envision the ideal state of the Fujifilm Group in FY2030 as a collection of global top-tier businesses that further enhances the corporate value of the Group by promoting management that emphasizes profitability and capital efficiency, while changing the world one step at a time and creating value (more smiles) for various stakeholders. In FY2025, the second year of VISION2030, we achieved record highs for the fourth consecutive year in revenue, fifth consecutive year in operating income, and sixth consecutive year in net income attributable to FUJIFILM Holdings. We are making steady progress towards achieving VISION2030 by allocating funds secured through stronger portfolio management and cash flow management to capital expenditure in growth areas, primarily the bio CDMO and semiconductor materials businesses.

    In FY2026, the global economy remained highly uncertain, reflecting various geopolitical factors, including the situations in Russia and Ukraine and Israel and Palestine, as well as growing concerns over a prolonged instability surrounding Iran. Other factors included volatility in energy markets, structural social shifts driven by the rapid advancement of artificial intelligence (AI), the rise of protectionist trade policies in various nations, and the tightening of resource security regarding rare earths and other critical resources. In Japan, while wage hikes and positive interest rates are gradually becoming the norm, the prolonged depreciation of the yen has led to surging raw material costs, forcing price revisions across numerous products. Under these circumstances, the Group will anticipate potential risks by maintaining a flexible and agile posture that quickly responds to various changes, as well as leverage our diverse business portfolio to improve the profitability of all businesses, promote stable cash generation, and evolve into a profitable company by accelerating business growth in the Healthcare and Electronics segments and intensifying our efforts to build a robust business platform that enables sustainable growth.

    [Growth Strategy in the Healthcare Segment]

    In the Healthcare segment, we will continue to provide products and services based on our proprietary AI technology, biotechnology and other cutting-edge technologies to resolve social issues in the medical field, such as enhancing QOL (quality of life) in an aging society and improving the medical environment in emerging countries. Through these efforts, we aim to increase revenue in the Healthcare segment in FY2026, exceeding ¥1 trillion in revenue for the third consecutive year following FY2024 and FY2025.

    In the medical systems business, we will utilize AI and imaging technologies as the foundation for creating

    value, introducing them in medical devices and IT services to offer new clinical value (including pre- and intraoperative support solutions) that only we can provide, while steadily expanding our recurring revenue businesses, such as services and consumables. Furthermore, our NURA health screening centers, which are geared towards emerging markets and have been released in five countries, have succeeded in providing consistent, high-quality checkups regardless of country or region, thanks to AI-powered diagnostic support as well as cutting-edge equipment such as CT scanners that feature our proprietary AI and deliver quality images by removing noise. We will continue to elevate the competitive advantage of the medical systems business through NURA, not only by providing value as a health screening business but also by incorporating the on-site challenges and latent needs identified through NURA's operations into the advancement of AI technology and new product development.

    In the bio CDMO business, to meet the strong demand for antibody drugs, we launched a new large-scale manufacturing plant at our North Carolina site in the United States. in FY2025, following the capacity enhancement at our Denmark site in FY2024. The plant began operations of eight 20,000-liter mammalian cell culture bioreactors, representing the first phase investment. Contract manufacturing is steadily progressing in North Carolina, having concluded, among others, long-term manufacturing agreements with Janssen Supply Group, LLC, a Johnson & Johnson company, and Regeneron Pharmaceuticals, Inc. Against the backdrop of growing manufacturing demand in the U.S., we are working to bring forward the start of operations for facilities of the second phase of capital investments at this site. While FY2026 will be another year of upfront investments, we will expedite our business growth with large-scale manufacturing facilities as the main drivers.

    In the LS solutions business, the life sciences business provides to major pharmaceutical companies and biotech firms culture media, reagents, cells and various other products and services that support different development stages, ranging from basic research and manufacturing to safety and quality testing, with the aim of meeting clients' needs in the field of drug discovery support. In the pharmaceutical business, we will continue to expand the manufacturing and sales of antibacterial agents such as penicillin. In addition, in 2025, we have completed the construction of one of the largest bio CDMO plants in Japan by adaptively reusing our existing Toyama site, with operations scheduled to begin from FY2027. At the new plant, we will establish a dual-use system capable of manufacturing biopharmaceuticals, such as antibody drugs and antibody-drug conjugates (ADCs), to meet customer needs during normal times, and mRNA vaccines and recombinant protein vaccines during pandemics. In the CRO business, we will expand our distinctive services, which make full use of, among others, evaluation technologies utilizing AI and iPS cells, both domestically and internationally by leveraging our proprietary peptide discovery technology as a core competency, primarily targeting customers engaged in the early stages of drug discovery, from basic research to non-clinical trials. In the consumer healthcare business, we will strengthen mail-order sales of our flagship brands, ASTALIFT (cosmetics) and Metabarrier (supplements), and expand sales of ASTALIFT MEN (cosmetics for men) and Hizatect (foods with functional claims).

    [Growth Strategy in the Electronics Segment]

    In the Electronics segment, we will expand existing businesses and develop new businesses under the Electronics Strategy Headquarters through product portfolio establishment and strategy management on a customer application basis.

    Demand has continued to grow in the semiconductor market, particularly for AI semiconductors. We expect that both miniaturization and higher integration in back-end processes will accelerate to improve semiconductor performance. To expedite the growth of our semiconductor materials business, we will leverage our strength in providing materials to nearly all stages in the semiconductor manufacturing process to offer one-stop solutions that help customers solve complex problems that cannot be addressed by a single material. Furthermore, by prioritizing local production, local consumption and "local support*2," our proactive investments in sites in Japan, the U.S., Europe and Asia not only support our customers' growth but also contribute to mitigating geopolitical risks, such as supply chain disruptions caused by conflicts. In addition, we are actively working to develop new markets, such as

    steadily preparing for local expansion in India, including the acquisition of land for manufacturing sites, as the semiconductor market is expected to grow there. Regarding our core product, photoresists, we presented the latest technologies for advanced photoresists, with a focus on next-generation EUV technology, at SPIE Advanced Lithography + Patterning 2026, an international conference on semiconductor-related technologies held in February 2026. Moreover, in April 2026, we announced the development of the world's first PFAS-free negative-type ArF immersion resist. EUV, ArF and other new technologies have received high praise from customers, and the number of inquiries is steadily increasing. With respect to back-end materials, demand for polyimide films is anticipated to rise in response to the trend toward larger interposers and the growing need for the miniaturization of build-up substrates. Further, our CMP slurries that provide high-precision planarization during hybrid bonding, an advanced packaging process, are currently undergoing evaluation for their use. Multiple customers have voiced their high expectations regarding these materials. We have also begun full-scale sample assessments for advanced packaging, and efforts toward adoption are steadily growing.

    In the AF materials business, we will maintain our strong market position of TAC products for displays and increase our share of materials for OLEDs. We will also leverage our technologies, such as data tape used in data centers-which are now being established worldwide due to increased demand for storage-the Prescale pressure measurement film used in the manufacturing process of semiconductors, displays, and other electronic devices, as well as polymers and photo acid generators for the growing semiconductor materials market, to expand the supply of differentiated products in the electronics sector.

    *2 "Local support" refers to the support structure that enables customer issues to be addressed directly at local sites.

    [Growth Strategy in the Business Innovation Segment]

    In the Business Innovation segment, we began in FY2025 a full-scale adoption of AI for its application to devices and solutions, creating unique value as the industry's sole solutions partner that covers all areas of printing, from office and commercial printing (analog/digital) to industrial printing. In light of changes in the business environment, we will thoroughly advance structural reforms while shifting management resources more rapidly toward growth areas to establish a foundation for sustainable growth.

    In the business solutions business, we will promote AI and security as the growth drivers across core systems, IT, and operational domains, while offering solutions tailored to each customer's business stage, thereby boosting value we provide and expanding our recurring business model. In the ERP solutions domain, we acquired ETG Global Information Technology Services Inc. in March 2026 (renamed to FUJIFILM ETG Global Inc. in the same month) to boost our delivery framework for ERP systems with Microsoft Dynamics 365 as its backbone. Going forward, we will expand our business into Europe and North America to accelerate our global presence. With respect to the IT solutions domain, we have launched IT Expert Services to support the operation and management of IT infrastructure environment for small and medium-sized companies that lack IT resources. In the business solutions domain, we are offering FUJIFILM IWpro, a cloud service that supports the cloud migration of our customers' infrastructure, as well as their business process transformation and DX. Since launching the FUJIFILM IWpro Intelligent Assistant option in January 2025, we have been continuously enhancing its AI capabilities. In March 2026, we added an AI chat feature, offering new value to our customers.

    In the office solutions business, amid a gradual decline in print volumes, we will focus on the A3 color field, where we have a leading market share, and work to strengthen our environmental initiatives and production base. In sales, we will maintain and improve profitability by shifting to a more efficient sales structure and aim to expand sales of multifunctional devices in new markets by signing new agency contracts with major distributors in European countries and North America and by acquiring new OEM deals. In addition, as part of efforts to enhance services through the use of AI, we have started developing a new printing support feature that leverages Microsoft Copilot, Microsoft's generative AI assistant. This printing feature enhances the convenience of multifunction printers in Seven-Eleven convenience stores nationwide and we are aiming to launch it in FY2026. We will

    continue promoting initiatives that expand the services we offer with our multifunction printers through the use of AI and other digital technologies.

    In the graphic communications business, we are responding to changing trends in the commercial and packaging printing markets. Amid the decline in large-lot analog printing and monochrome printing and the increasing demand for high-mix, small-lot printing and color printing, we will expand sales by leveraging our strong customer base, where we hold leading market shares in printing plates, digital printers and industrial printheads, and further accelerating the shift to digital. In December 2025, we launched Revoria Press PC2120 in Japan as a flagship model for the high-end professional printing market. Regarding inkjet inks and printheads, we will improve profitability by reorganizing the production structure. In parallel, we will leverage our unique products and technologies, such as high-productivity and high-quality printheads, as well as the highly stable aqueous pigment dispersion technology, to expand our business in the growing digital commercial and packaging printing markets, as well as in new areas where we expect market expansion through the advancement of inkjet technology.

    [Growth Strategy in the Imaging Segment]

    In the consumer imaging business, we will continue to expand our user base by constantly introducing captivating new products, including instax mini LiPlay+ (launched in November 2025), a hybrid instant camera that comes with an advanced version of a feature that combines sound and still images, and instax mini Evo Cinema (launched in January 2026), an instant camera that can take both videos (which users can "hand over" to others) and still images, and is equipped with the Eras Dial that recreates the appearance of footage from the 1930s to the current decade. In addition, we will continue to tap into new printing demand by further expanding sales of commercial photo printers and creating new touchpoints with younger generations through alliances across various industries.

    In the professional imaging business, we aim to grow our fan base by enhancing the multi-brand digital camera strategy, centered around the X Series and the GFX Series of digital cameras featuring color reproduction optimized for digital imaging, to meet emerging demand for more than just smartphone photography. Furthermore, with the launch of FUJIFILM GFX ETERNA 55 in October 2025, our first dedicated filmmaking camera, we have made a full-scale entry into the video production market. The camera's rich gradation and three-dimensional image expression have been well received both in Japan and internationally. In addition, we will promote new applications and expand sales areas for projectors and long-range surveillance cameras, while also proactively launching new solutions such as infrastructure inspection DX, utilizing the cutting-edge optical technology, image processing technology and AI.

  4. BASIC RATIONALE FOR SELECTION OF ACCOUNTING STANDARDS

    Due to the agreement related to the Eurodollar convertible bond issuance in 1970, the Group has prepared and disclosed its consolidated financial statements in accordance with accounting principles generally accepted in the

    U.S. The Company is considering the adoption of IFRS through addressing internal and external factors that affect both within and outside of Japan.

  5. CONSOLIDATED FINANCIAL STATEMENTS

  1. Consolidated Balance Sheets Amount Unit: Millions of yen

    As of

    March 31, 2026

    As of

    March 31, 2025

    Change

    ASSETS

    Current assets:

    Cash and cash equivalents

    170,553

    172,111

    (1,558)

    Notes and accounts receivable:

    Trade

    742,721

    680,635

    62,086

    Lease receivable

    31,750

    32,821

    (1,071)

    Affiliated companies

    2,737

    2,371

    366

    Allowance for credit losses

    (14,693)

    (15,841)

    1,148

    Inventories

    762,515

    600,796

    699,986

    543,976

    62,529

    56,820

    Prepaid expenses and Other

    185,169

    165,608

    19,561

    Total current assets

    1,719,033

    1,581,681

    137,352

    Investments and long-term receivables:

    Investments in and advances to affiliated

    companies

    37,617

    37,785

    (168)

    Investment securities

    43,672

    72,298

    (28,626)

    Long-term lease receivables

    49,181

    47,431

    1,750

    Other long-term receivables

    76,831

    53,176

    23,655

    Allowance for credit losses

    (1,511)

    (1,396)

    (115)

    Total investments and long-term

    205,790

    209,294

    (3,504)

    receivables

    Property, plant and equipment:

    Land

    121,419

    110,067

    11,352

    Buildings and structures

    1,173,654

    934,470

    239,184

    Machinery, equipment and others

    1,989,906

    1,717,518

    272,388

    Construction in progress

    979,735

    888,245

    91,490

    Less accumulated depreciation

    4,264,714

    (1,956,406)

    3,650,300

    (1,863,825)

    614,414

    (92,581)

    Total property, plant and equipment

    2,308,308

    1,786,475

    521,833

    Other assets:

    Operating lease right-of-use assets

    130,157

    113,476

    16,681

    Goodwill, net

    997,068

    947,924

    49,144

    Other intangible assets, net

    151,175

    157,547

    (6,372)

    Deferred income taxes

    41,210

    42,895

    (1,685)

    Other

    501,035

    410,616

    90,419

    Total other assets

    1,820,645

    1,672,458

    148,187

    Total assets

    6,053,776

    5,249,908

    803,868

    Amount Unit: Millions of yen

    As of

    March 31, 2026

    As of

    March 31, 2025

    Change

    LIABILITIES

    Current liabilities:

    Short-term debt

    287,913

    215,103

    72,810

    Notes and accounts payable:

    Trade

    291,296

    279,362

    11,934

    Construction

    97,154

    109,543

    (12,389)

    Affiliated companies

    1,399

    1,672

    (273)

    Accrued income taxes

    389,849

    53,202

    390,577

    32,701

    (728)

    20,501

    Accrued liabilities

    280,017

    252,788

    27,229

    Short-term operating lease liabilities

    36,549

    31,582

    4,967

    Other current liabilities

    210,742

    203,189

    7,553

    Total current liabilities

    1,258,272

    1,125,940

    132,332

    Non-current liabilities:

    Long-term debt

    607,034

    470,805

    136,229

    Accrued pension and severance costs

    25,515

    25,368

    147

    Long-term operating lease liabilities

    95,517

    84,795

    10,722

    Deferred income taxes

    128,442

    101,437

    27,005

    Other non-current liabilities

    94,611

    88,881

    5,730

    Total non-current liabilities

    951,119

    771,286

    179,833

    Total liabilities

    2,209,391

    1,897,226

    312,165

    EQUITY

    FUJIFILM Holdings shareholders' equity

    Capital

    40,363

    40,363

    -

    Common stock, without par value:

    Authorized: 2,400,000,000 shares

    Issued: 1,243,877,184 shares

    Retained earnings

    3,117,407

    2,930,151

    187,256

    Accumulated other comprehensive income

    736,167

    433,047

    303,120

    Treasury stock, at cost

    As of March 31, 2025:

    39,043,399 shares

    As of March 31, 2026:

    38,547,368 shares

    (54,387)

    (55,081)

    694

    Total FUJIFILM Holdings shareholders'

    3,839,550

    3,348,480

    491,070

    equity

    Noncontrolling interests

    4,835

    4,202

    633

    Total equity

    3,844,385

    3,352,682

    491,703

    Total liabilities and equity

    6,053,776

    5,249,908

    803,868

    Note: Details of accumulated other comprehensive income (loss)

    As of March 31, 2026

    As of March 31, 2025

    Change

    Foreign currency translation adjustments

    694,154

    433,944

    260,210

    Pension liability adjustments

    42,013

    (862)

    42,875

    Unrealized gains (losses) on derivatives

    -

    (35)

    35

  2. Consolidated Statements of Income and Consolidated Statements of Comprehensive Income (Consolidated Statements of Income) Year Ended March 31 Amount Unit: Millions of yen

    Year ended March 31, 2026

    From April 1, 2025

    to March 31, 2026

    Year ended March 31, 2025

    From April 1, 2024

    to March 31, 2025

    Change

    Amount

    %

    %

    %

    Revenue:

    100.0 3,356,969

    100.0 3,195,828

    161,141

    5.0

    Cost of sales:

    59.2 1,987,457

    59.3 1,895,749

    91,708

    4.8

    Gross profit

    40.8 1,369,512

    40.7 1,300,079

    69,433

    5.3

    Operating expenses:

    Selling, general and administrative

    25.7 861,512

    25.2 806,525

    54,987

    6.8

    Research and development

    4.7 157,790

    5.1 163,399

    (5,609)

    (3.4)

    30.4 1,019,302

    30.3 969,924

    49,378

    5.1

    Operating income

    10.4 350,210

    10.3 330,155

    20,055

    6.1

    Other income (expenses):

    Interest and dividend income

    11,222

    13,380

    (2,158)

    Interest expense

    (4,993)

    (8,752)

    3,759

    Foreign exchange gains (losses), net

    (3,730)

    (3,909)

    179

    Gains (losses) on equity securities, net

    (714)

    (3,107)

    2,393

    Other, net

    14,634

    12,827

    1,807

    0.5 16,419

    0.3 10,439

    5,980

    57.3

    Income before income taxes

    10.9 366,629

    10.7 340,594

    26,035

    7.6

    Income taxes

    Current

    80,713

    81,809

    (1,096)

    Deferred

    10,548

    (4,214)

    14,762

    2.7 91,261

    2.4 77,595

    13,666

    17.6

    Equity in net earnings (losses) of affiliated companies

    0.1 1,929

    0.0 (1,320)

    3,249

    -

    Net income

    8.3 277,297

    8.2 261,679

    15,618

    6.0

    Less: Net (income) loss attributable to the noncontrolling interests

    0.0 (562)

    0.0 (728)

    166

    -

    Net income attributable to

    FUJIFILM Holdings

    8.2 276,735

    8.2 260,951

    15,784

    6.0

    Three Months Ended March 31 Amount Unit: Millions of yen

    Three months ended March 31, 2026

    From January 1, 2026

    to March 31, 2026

    Three months ended March 31, 2025

    From January 1, 2025

    to March 31, 2025

    Change

    Amount

    %

    %

    %

    Revenue:

    100.0 927,252

    100.0 868,309

    58,943

    6.8

    Cost of sales:

    59.4 550,582

    60.3 523,983

    26,599

    5.1

    Gross profit

    40.6 376,670

    39.7 344,326

    32,344

    9.4

    Operating expenses:

    Selling, general and administrative

    25.5 236,136

    22.5 195,513

    40,623

    20.8

    Research and development

    4.2 38,775

    4.8 41,937

    (3,162)

    (7.5)

    29.6 274,911

    27.3 237,450

    37,461

    15.8

    Operating income

    11.0 101,759

    12.3 106,876

    (5,117)

    (4.8)

    Other income (expenses):

    Interest and dividend income

    1,452

    3,075

    (1,623)

    Interest expense

    (863)

    (2,610)

    1,747

    Foreign exchange gains (losses), net

    645

    (5,590)

    6,235

    Gains (losses) on equity securities, net

    (1,661)

    (2,287)

    626

    Other, net

    3,107

    3,983

    (876)

    0.3 2,680

    (0.4) (3,429)

    6,109

    -

    Income before income taxes

    11.3 104,439

    11.9 103,447

    992

    1.0

    Income taxes

    2.1 19,650

    2.6 22,777

    (3,127)

    (13.7)

    Equity in net earnings (losses) of affiliated companies

    (0.1) (1,284)

    (0.1) (1,172)

    (112)

    -

    Net income

    9.0 83,505

    9.2 79,498

    4,007

    5.0

    Less: Net (income) loss attributable to the noncontrolling interests

    0.0 (145)

    0.0 (86)

    (59)

    -

    Net income attributable to

    FUJIFILM Holdings

    9.0 83,360

    9.1 79,412

    3,948

    5.0

    (Consolidated Statements of Comprehensive Income) Year Ended March 31 Amount Unit: Millions of yen

    Year ended March 31, 2026

    From April 1, 2025

    to March 31, 2026

    Year ended March 31, 2025

    From April 1, 2024

    to March 31, 2025

    Change

    Net income

    277,297

    261,679

    15,618

    Other comprehensive income (loss), net of tax:

    Foreign currency translation adjustments

    260,471

    (31,357)

    291,828

    Pension liability adjustments

    42,875

    20,635

    22,240

    Unrealized gains (losses) on derivatives

    35

    (33)

    68

    Total

    303,381

    (10,755)

    314,136

    Comprehensive income

    580,678

    250,924

    329,754

    Less: Comprehensive (income) loss attributable to noncontrolling interests

    (823)

    (545)

    (278)

    Comprehensive income attributable to

    FUJIFILM Holdings

    579,855

    250,379

    329,476

    Three Months Ended March 31 Amount Unit: Millions of yen

    Three months ended March 31, 2026

    From January 1, 2026

    to March 31, 2026

    Three months ended March 31, 2025

    From January 1, 2025

    to March 31, 2025

    Change

    Net income

    83,505

    79,498

    4,007

    Other comprehensive income (loss), net of tax:

    Foreign currency translation adjustments

    34,101

    (109,185)

    143,286

    Pension liability adjustments

    43,539

    21,344

    22,195

    Unrealized gains (losses) on derivatives

    -

    (173)

    173

    Total

    77,640

    (88,014)

    165,654

    Comprehensive income (loss)

    161,145

    (8,516)

    169,661

    Less: Comprehensive (income) loss attributable to noncontrolling interests

    (158)

    117

    (275)

    Comprehensive income (loss) attributable to

    FUJIFILM Holdings

    160,987

    (8,399)

    169,386

  3. Consolidated Statements of Changes in Shareholders' Equity Amount Unit: Millions of yen

    Common stock

    Additional paid-in capital

    Retained earnings

    Accumulated other comprehensive income (loss)

    Treasury stock

    FUJIFILM

    Holdings shareholders' equity

    Noncontrolling interest

    Total Equity

    Balanced at April 1, 2024

    40,363

    -

    2,741,416

    443,619

    (56,151)

    3,169,247

    4,068

    3,173,315

    Comprehensive income (loss):

    260,951

    (31,174)

    20,635

    (33)

    260,951

    (31,174)

    20,635

    (33)

    728

    (183)

    261,679

    (31,357)

    20,635

    (33)

    Net income

    Foreign currency translation adjustments

    Pension liability adjustments Change in net unrealized losses

    on derivatives

    Net comprehensive income

    250,379

    545

    250,924

    Purchases of treasury stock

    (16)

    (16)

    (16)

    Sales of treasury stock

    1,151

    1,086

    2,237

    2,237

    Dividends paid to FUJIFILM

    Holdings shareholders

    (72,289)

    (72,289)

    (72,289)

    Dividends paid to noncontrolling

    interests

    (291)

    (291)

    Stock acquisition rights

    (697)

    (697)

    (697)

    Transfer from additional paid-in

    capital

    (73)

    73

    -

    -

    to retained earnings

    Equity transactions with non

    controlling interests and other

    (381)

    (381)

    (120)

    (501)

    Balanced at March 31, 2025

    40,363

    -

    2,930,151

    433,047

    (55,081)

    3,348,480

    4,202

    3,352,682

    Comprehensive income (loss):

    276,735

    260,210

    42,875

    35

    276,735

    260,210

    42,875

    35

    562

    261

    277,297

    260,471

    42,875

    35

    Net income

    Foreign currency translation adjustments

    Pension liability adjustments Change in net unrealized losses

    on derivatives

    Net comprehensive income

    579,855

    823

    580,678

    Purchases of treasury stock

    (11)

    (11)

    (11)

    Sales of treasury stock

    694

    705

    1,399

    1,399

    Dividends paid to FUJIFILM

    Holdings shareholders

    (90,396)

    (90,396)

    (90,396)

    Dividends paid to noncontrolling

    interests

    (332)

    (332)

    Stock acquisition rights

    223

    223

    223

    Transfer from additional paid-in

    capital

    (917)

    917

    -

    -

    to retained earnings

    Equity transactions with non

    controlling interests and other

    142

    142

    Balanced at March 31, 2026

    40,363

    -

    3,117,407

    736,167

    (54,387)

    3,839,550

    4,835

    3,844,385

  4. Consolidated Statements of Cash Flows Amount Unit: Millions of yen

    Year ended March 31, 2026

    From April 1, 2025

    to March 31, 2026

    Year ended March 31, 2025

    From April 1, 2024

    to March 31, 2025

    Change

    Operating activities

    Net income

    277,297

    261,679

    15,618

    Adjustments to reconcile net income to net cash

    provided by operating activities:

    Depreciation and amortization (Gains) losses on equity securities, net Deferred income taxes

    Equity in net (gains) losses of affiliated companies, net of dividends received Changes in operating assets and liabilities:

    Notes and accounts receivable Inventories

    Notes and accounts payable - trade

    Changes in prepaid expenses and other current assets

    Accrued income taxes and other liabilities Others

    172,371

    163,567

    8,804

    716

    3,107

    (2,391)

    10,548

    (4,214)

    14,762

    (995)

    1,856

    (2,851)

    (23,942)

    (5,348)

    (18,594)

    (23,858)

    (310)

    (23,548)

    123

    18,254

    (18,131)

    (6,144)

    (11,667)

    5,523

    15,435

    22,615

    (7,180)

    (10,996)

    (21,377)

    10,381

    Subtotal

    133,258

    166,483

    (33,225)

    Net cash provided by operating activities

    410,555

    (521,583)

    (48,983)

    14,073

    32,509

    (5,650)

    (2,781)

    (181)

    (6,113)

    7,752

    (23,647)

    428,162

    (502,794)

    (55,211)

    33,926

    8,705

    (462)

    297

    (42)

    (3,873)

    -(22,499)

    (17,607)

    (18,789)

    6,228

    (19,853)

    23,804

    (5,188)

    (3,078)

    (139)

    (2,240)

    7,752

    (1,148)

    Investing activities

    Purchases of property, plant and equipment

    Purchases of software

    Sales of property, plant and equipment

    Proceeds from sales and maturities of marketable

    and investment securities

    Purchases of marketable and investment

    securities

    (Increase) decrease in time deposits, net

    Increase in investments in and advances to

    affiliated companies

    Acquisitions of businesses, net of cash acquired

    Proceeds from sale of businesses, net of cash and

    cash equivalents disposed of

    Others

    Net cash used in investing activities

    (554,604)

    (541,953)

    (12,651)

    Financing activities

    Proceeds from long-term debt

    170,000

    350,000

    (180,000)

    Repayments of long-term debt

    (67,602)

    (82,320)

    14,718

    Increase (decrease) in short-term debt, net

    102,324

    (86,625)

    188,949

    Cash dividends paid to shareholders

    (84,354)

    (68,252)

    (16,102)

    Subsidiaries' cash dividends paid to

    noncontrolling interests

    (332)

    (292)

    (40)

    Purchases of stock for treasury

    (12)

    (16)

    4

    Capital transactions with noncontrolling interests

    141

    (671)

    812

    Others

    84

    (2,941)

    3,025

    Net cash provided by financing activities

    120,249

    108,883

    11,366

    Effect of exchange rate changes on cash and cash

    equivalents

    22,242

    (2,696)

    24,938

    Net decrease in cash and cash equivalents

    (1,558)

    (7,604)

    6,046

    Cash and cash equivalents at beginning of year

    172,111

    179,715

    (7,604)

    Cash and cash equivalents at end of year

    170,553

    172,111

    (1,558)

  5. Notes to Consolidated Financial Statements (Note Relating to the Going Concern Assumption)

    None.

    (Summary of Significant Accounting Policies)

    1. Scope of consolidated subsidiaries Number of Subsidiaries : 258

      Main companies : FUJIFILM Corporation, FUJIFILM Business Innovation Corp.

      FUJIFILM Business Innovation Japan Corp. and others

    2. Scope of affiliated companies Number of Affiliates 27

      Main companies : FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. and others

    3. Significant Accounting Policies

The Company's consolidated financial statements are prepared in accordance with the U.S. generally accepted accounting pirnciples (US GAAP). As there have been no material changes from the matters described in the most recent Annual Securities Report filed on June 25, 2025, disclosure thereof is omitted.

(Segment Information)
  1. Year Ended March 31 (A) Operating Segment Information
    1. Revenue Amount Unit: Millions of yen

      Year ended March 31, 2026

      From April 1, 2025

      to March 31, 2026

      Year ended March 31, 2025

      From April 1, 2024

      to March 31, 2025

      Change

      Amount

      %

      Revenue:

      Composition (%)

      Composition (%)

      Healthcare

      32.7

      1,098,925

      32.8

      1,047,754

      51,171

      4.9

      Electronics

      13.6

      456,157

      12.8

      407,607

      48,550

      11.9

      Business Innovation

      35.0

      1,174,800

      37.5

      1,198,494

      (23,694)

      (2.0)

      Imaging

      18.7

      627,087

      17.0

      541,973

      85,114

      15.7

      Consolidated total

      100.0

      3,356,969

      100.0

      3,195,828

      161,141

      5.0

    2. Expenses Amount Unit: Millions of yen

      Year ended March 31, 2026

      From April 1, 2025

      to March 31, 2026

      Year ended March 31, 2025

      From April 1, 2024

      to March 31, 2025

      Change

      Amount

      %

      R&D expenses

      53,346

      28,209

      55,406

      13,366

      61,279

      25,179

      54,507

      13,329

      (7,933)

      3,030

      899

      37

      (12.9)

      12.0

      1.6

      0.3

      Healthcare Electronics Business Innovation

      Imaging

      Subtotal

      Corporate

      150,327

      7,463

      154,294

      9,105

      (3,967)

      (1,642)

      (2.6)

      (18.0)

      Consolidated total

      157,790

      163,399

      (5,609)

      (3.4)

      Other operating expenses

      981,942

      327,065

      1,055,682

      453,718

      906,593

      307,360

      1,069,373

      389,430

      75,349

      19,705

      (13,691)

      64,288

      8.3

      6.4

      (1.3)

      16.5

      Healthcare Electronics Business Innovation

      Imaging

      Subtotal

      Corporate

      2,818,407

      30,562

      2,672,756

      29,518

      145,651

      1,044

      5.4

      3.5

      Consolidated total

      2,848,969

      2,702,274

      146,695

      5.4

    3. Operating income Amount Unit: Millions of yen

      Year ended March 31, 2026

      From April 1, 2025

      to March 31, 2026

      Year ended

      March 31, 2025

      From April 1, 2024

      to March 31, 2025

      Change

      Amount

      %

      Operating Income (Loss):

      Margin (%)

      5.8

      22.1

      5.4

      25.5

      63,637

      100,883

      63,712

      160,003

      Margin (%)

      7.6

      18.4

      6.2

      25.7

      79,882

      75,068

      74,614

      139,214

      (16,245)

      25,815

      (10,902)

      20,789

      (20.3)

      34.4

      (14.6)

      14.9

      Healthcare

      Electronics Business Innovation Imaging

      Total

      Corporate expenses etc.

      388,235

      (38,025)

      368,778

      (38,623)

      19,457

      598

      5.3

      -

      Consolidated total 10.4

      350,210

      10.3

      330,155

      20,055

      6.1

      Note: The major products and services of each operating segment are as follows: Healthcare: Equipment and materials for medical systems,

      contract development and manufacturing organization of biopharmaceuticals, drug discovery support such as iPS cells, cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.

      Electronics: Semiconductor materials, display materials, industrial equipment, fine chemicals, etc.

      Business Innovation: Solutions and services, digital MFPs,

      equipment and materials for graphic communications, inks and industrial inkjet printheads, etc

      Imaging: Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

    4. Total Assets Amount Unit: Millions of yen

      As of March 31, 2026

      As of March 31, 2025

      Change

      Amount

      %

      Total assets:

      3,227,034

      821,265

      1,469,229

      423,126

      2,607,431

      761,391

      1,373,286

      364,437

      619,603

      59,874

      95,943

      58,689

      23.8

      7.9

      7.0

      16.1

      Healthcare

      Electronics Business Innovation Imaging

      Subtotal

      Corporate

      5,940,654

      113,122

      5,106,545

      143,363

      834,109

      (30,241)

      16.3

      (21.1)

      Consolidated total 6,053,776

      5,249,908

      803,868

      15.3

    5. Depreciation and amortization, and Capital expenditures Amount Unit: Millions of yen

      Year ended March 31, 2026

      From April 1, 2025

      to March 31, 2026

      Year ended March 31, 2025

      From April 1, 2024

      to March 31, 2025

      Change

      Amount

      %

      Depreciation and amortization:

      Healthcare

      74,461

      62,739

      11,722

      18.7

      Electronics

      30,677

      28,704

      1,973

      6.9

      Business Innovation

      45,754

      51,776

      (6,022)

      (11.6)

      Imaging

      17,181

      17,382

      (201)

      (1.2)

      Corporate

      4,298

      2,966

      1,332

      44.9

      Consolidated total

      172,371

      163,567

      8,804

      5.4

      Capital expenditures:

      Healthcare

      444,685

      465,883

      (21,198)

      (4.6)

      Electronics

      38,533

      40,284

      (1,751)

      (4.3)

      Business Innovation

      63,821

      73,035

      (9,214)

      (12.6)

      Imaging

      29,031

      21,602

      7,429

      34.4

      Corporate

      5,906

      6,377

      (471)

      (7.4)

      Consolidated total

      581,976

      607,181

      (25,205)

      (4.2)

      *From the consolidated first three months of the fiscal year, the chemical reagents business was reclassified from the Electronics segment, where it was included in the AF aterials business, to the Healthcare segment. Figures for the year-ago quarter are also based on the segment classification after the above change.

      (B) Geographic Information
      1. Long - lived assets Amount Unit: Millions of yen

        As of March 31, 2026

        As of March 31, 2025

        Change

        Amount

        %

        Long - lived assets

        Japan

        432,956

        408,084

        24,872

        6.1

        The Americas

        882,660

        643,690

        238,970

        37.1

        Europe

        911,253

        664,752

        246,501

        37.1

        Asia and others

        81,439

        69,949

        11,490

        16.4

        Consolidated total

        2,308,308

        1,786,475

        521,833

        29.2

      2. Overseas revenue (Destination Base) Amount Unit: Millions of yen

      Year ended March 31, 2026

      From April 1, 2025

      to March 31, 2026

      Year ended

      March 31, 2025

      From April 1, 2024

      to March 31, 2025

      Change

      Amount

      %

      Revenue:

      Domestic Overseas:

      Composition (%)

      34.8

      19.6

      17.3

      28.3

      1,168,682

      657,898

      581,133

      949,256

      Composition (%)

      34.4

      20.2

      17.0

      28.3

      1,099,302

      646,904

      544,628

      904,994

      69,380

      10,994

      36,505

      44,262

      6.3

      1.7

      6.7

      4.9

      The Americas

      Europe

      Asia and others

      Subtotal

      65.2

      2,188,287

      65.6

      2,096,526

      91,761

      4.4

      Consolidated total 100.0

      3,356,969

      100.0

      3,195,828

      161,141

      5.0

      Note: The presentation of the Overseas Revenue (Destination Base) has been classified and disclosed based on the customer's location.

  2. Three months ended March 31
  1. Operating Segment Information Revenue Amount Unit: Millions of yen

    Three months ended March 31, 2026

    From January 1, 2026

    to March 31, 2026

    Three months ended

    March 31, 2025

    From January 1, 2025

    to March 31, 2025

    Change

    Amount

    %

    Revenue:

    Composition (%)

    Composition (%)

    Healthcare

    36.0

    333,606

    36.4

    316,454

    17,152

    5.4

    Electronics

    13.7

    127,482

    11.5

    100,099

    27,383

    27.4

    Business Innovation

    35.0

    324,783

    38.7

    336,446

    (11,663)

    (3.5)

    Imaging

    15.2

    141,381

    13.3

    115,310

    26,071

    22.6

    Consolidated total

    100.0

    927,252

    100.0

    868,309

    58,943

    6.8

    * From the consolidated first three months of the fiscal year, the chemical reagents business was reclassified from the Electronics segment, where it was included in the AF Materials business, to the Healthcare segment. Figures for the year-ago quarter are also based on the segment classification after the above change.

    Note: The major products and services of each operating segment are as follows: Healthcare: Equipment and materials for medical systems,

    contract development and manufacturing organization of biopharmaceuticals, drug discovery support such as iPS cells, cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.

    Electronics: Semiconductor materials, display materials, industrial equipment, fine chemicals, etc

    Business Innovation: Solutions and services, digital MFPs,

    equipment and materials for graphic communications, inks and industrial inkjet printheads, etc.

    Imaging: Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

  2. Geographic Information
Overseas Revenue (Destination Base) Amount Unit: Millions of yen

Three months ended March 31, 2026

From January 1, 2026

to March 31, 2026

Three months ended

March 31, 2025

From January 1, 2025

to March 31, 2025

Change

Amount

%

Revenue:

Domestic Overseas:

Composition (%)

37.0

18.5

16.6

27.9

342,771

171,881

154,017

258,583

Composition (%)

38.4

18.4

17.5

25.6

333,655

159,692

152,381

222,581

9,116

12,189

1,636

36,002

2.7

7.6

1.1

16.2

The Americas

Europe

Asia and others

Subtotal

63.0

584,481

61.6

534,654

49,827

9.3

Consolidated total 100.0

927,252

100.0

868,309

58,943

6.8

(Amounts Per Share of Common Stock)

FUJIFILM Holdings shareholders' equity per share

Basic net income attributable to FUJIFILM Holdings per share

Diluted net income attributable to FUJIFILM Holdings per share

Year ended March 31, 2026

From April 1, 2025 to

3,185.79

2,779.50

229.65

216.67

229.45

216.46

March 31, 2026

Year ended March 31, 2025

From April 1, 2024 to

March 31, 2025

(Significant Subsequent Events)

None.